YOLFTbeta
30

Sino BiologicalInc.

301047 · SHE · Healthcare / Biotechnology

99.20CNY-12.29 (-11.02%)

Price History

Full chart

Market Stats

Previous Close111.49
Open108.72
Day Range98.41 – 110.00
52-Week Range57.54 – 165.00
Volume7.78M
Market Cap19.34B
P/E (TTM)117.78
Forward P/E57.14
EPS1.35
Dividend Yield1.38%
Beta0.76
50-Day Avg104.77
200-Day Avg78.90

About

Sino Biological,Inc. engages in the provision of recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, comprehensive CAR-T therapy, 3D organoids research, ADC development, influenza vaccine development, and multispecific antibody development solutions, as well as solutions for MSCs therapy and in vitro efficacy evaluation. It serves academic research institutions, biotech companies, and pharmaceutical companies. Sino Biological,Inc. was founded in 2016 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Liangzhi Xie Ph.D.
  • Employees1.07K
  • HeadquartersBuilding 11, Beijing, China, 100176, China
  • Websitehttps://www.sinobiological.com

Leadership

  • Dr. Liangzhi Xie Ph.D.Founder & Chairman · b. 1966
  • Mr. Zhang Jie Ph.D.GM, Director of R&D and Director · b. 1973
  • Mr. Tao FengCFO, Secretary to the Board & Non-Independent Director · b. 1981
  • Mr. Zhou YongProduction Director · b. 1982
  • Xiaoming MaAccounting Supervisor & Head of Accounting Department

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue180.83M1.60B965.27M574.60M646.39M613.67M699.56M
Growth (%)-+782.77%-39.53%-40.47%+12.49%-5.06%+14.00%
Cost of Revenue28.94M49.79M58.24M86.04M115.98M163.92M186.85M
Gross Profit151.88M1.55B907.03M488.57M530.41M449.76M512.71M
Gross Margin83.99%96.88%93.97%85.03%82.06%73.29%73.29%
Operating Expense111.57M188.80M127.95M261.02M366.52M395.04M408.29M
Operating Income40.32M1.36B779.09M227.55M163.89M54.72M104.42M
Operating Margin22.30%85.05%80.71%39.60%25.35%8.92%14.93%
EBITDA84.03M1.37B873.83M383.39M361.51M236.28M273.81M
EBITDA Margin46.47%86.12%90.53%66.72%55.93%38.50%39.14%
Net Income36.41M1.13B720.01M302.96M260.13M121.93M147.74M
Net Income Margin20.14%70.64%74.59%52.72%40.24%19.87%21.12%
R&D23.28M26.06M40.13M60.15M87.45M91.21M86.22M
R&D as % of Total Revenue12.87%1.63%4.16%10.47%13.53%14.86%12.32%
Interest Expense--2.01M2.77M3.73M3.98M3.09M
Interest Expense % of Total Revenue--0.21%0.48%0.58%0.65%0.44%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets187.15M1.49B6.89B6.58B6.60B6.05B5.54B
Total Liabilities37.35M189.67M137.92M211.11M233.70M281.80M228.00M
Total Equity149.81M1.30B6.75B6.37B6.37B5.77B5.31B
Cash10.28M56.12M2.87B2.38B1.32B233.35M322.30M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow41.79M1.09B642.62M249.39M322.56M113.73M146.19M
Capital Expenditure33.64M18.34M47.90M156.06M1.04B69.95M101.05M
Free Cash Flow8.15M1.07B594.72M93.34M-720.80M43.78M45.14M
Dividends Paid20.78K--680.00M258.40M255.52M608.18M
FCF to OCF19.50%98.32%92.55%37.43%-223.46%38.50%30.88%
Dividend Paid to FCF0.26%--728.54%-35.85%583.58%1347.26%

Earnings

Report DateAug 27, 2021Oct 26, 2021Feb 27, 2022Apr 28, 2022Aug 11, 2022Oct 25, 2022Dec 31, 2022Apr 21, 2023Aug 27, 2023Oct 24, 2023Dec 31, 2023Apr 23, 2024Aug 9, 2024Sep 30, 2024Dec 31, 2024Apr 23, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------
EPS Actual0.860.881.270.881.150.650.210.210.400.540.430.340.210.230.190.190.370.350.310.260.44
Surprise---------------------
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-market-Pre-marketAfter-hoursPre-market-Pre-marketPre-market--Pre-market-----

Key Statistics & Ratios

Market Cap19.34B
Enterprise Value15.16B
Trailing P/E117.78
Forward P/E57.14
Price / Sales25.18
Price / Book3.49
EPS1.35
Book Value43.03
Revenue (TTM)768.00M
Gross Profit (TTM)563.40M
EBITDA183.12M
Profit Margin21.52%
Operating Margin15.90%
Return on Equity3.01%
Return on Assets1.32%
Shares Outstanding121.64M
Shares Float43.30M
Beta0.76
Dividend Yield1.38%
Dividend Rate2.20
Payout Ratio1.62%

Dividends

20261×
1.20May 15, 2026
20252×
4.00Sep 22, 20251.00May 20, 2025
20241×
2.00May 23, 2024
20231×
2.00May 24, 2023
20221×
10.00Mar 30, 2022

Stock Splits

  • Mar 30, 20221.9:1